Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26847886 | 0.93 | USP2 (0.43) | USP2SMN1; SMN2RECQLJAK3JAK1 | |
| SCHEMBL27088704 | 0.87 | USP2 (0.47) | USP2SMN1; SMN2RECQLJAK3JAK1 | |
| Hydrochloric Acid SCHEMBL31603642 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2RECQLJAK3CTSK | |
| SCHEMBL22409398 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2RECQLJAK3GRIN2B | |
| SCHEMBL19320637 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2RECQLJAK3JAK1 | |
| SCHEMBL3706160 | 0.83 | JAK3 (0.38) | USP2SMN1; SMN2JAK3GRIN2BGRIN2C | |
| SCHEMBL31200740 | 0.82 | USP2 (0.40) | USP2SMN1; SMN2RECQLJAK3 | |
| SCHEMBL700241 | 0.81 | JAK3 (0.43) | USP2SMN1; SMN2JAK3GRIN2BGRIN2C | |
| Hydrochloric Acid SCHEMBL19582520 | 0.79 | JAK3 (0.43) | USP2SMN1; SMN2JAK3GRIN2BGRIN2C | |
| SCHEMBL15286428 | 0.79 | JAK3 (0.46) | USP2SMN1; SMN2JAK3GRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4660192-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4620533-A2 | ANTAGONIST COMPOUNDS | Adorx therapeutics Limited (GB) | 2025-09-24 | — | — | EP | disclosed |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4188924-B1 | ANTAGONIST COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-06-18 | — | — | EP | disclosed |
| CN-119137118-A | Antagonists of adenosine receptors | 阿道尔克斯治疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4469452-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | Adorx therapeutics Limited (GB) | 2024-12-04 | — | — | EP | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| WO-2022031928-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022023772-A1 | ANTAGONIST COMPOUNDS | AdoRx Therapeutics Limited (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-9908897-B2 | Spirocyclic derivatives | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9908897-B2 | Spirocyclic derivatives | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| EP-3201195-A1 | SPIROCYCLIC DERIVATIVES | Chronos Therapeutics Limited (GB) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | USP2 2895/4885SMN1; SMN2 3965/4885RECQL 3905/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | USP2 3889/4885SMN1; SMN2 3476/4885RECQL 305/4885 |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | SGK1, SGK2, SIK1 | USP2 2031/4885SMN1; SMN2 2955/4885RECQL 4086/4885 |
| US-20170253615-A1 | Spirocyclic derivatives | SLC6A3, SLC10A1, ABCB11 | USP2 4814/4885SMN1; SMN2 3011/4885RECQL 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.